STAAR Surgical (STAA) Q2 FY26 earnings call

STAAR Surgical delivered a robust second quarter, achieving record first-half revenue and a strong return to profitability and free cash flow generation. The company demonstrated significant momentum in China with the EVO Plus launch driving market share gains, alongside solid performance in the Americas and EMEA. Management is focused on disciplined execution, expanding profitability, and accelerating innovation, including next-generation product development and a strategic CTO hire, to build a broader platform beyond its core EVO ICL offering.